Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Multiple medicine-resistant cell line for lung cancer

A multi-drug resistance and cell line technology, applied in the direction of tumor/cancer cells, animal cells, vertebrate cells, etc., can solve the problems of multi-drug resistance of tumors and poor treatment effect of lung cancer patients

Active Publication Date: 2006-12-27
HARBIN MEDICAL UNIVERSITY
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still some lung cancer patients with poor treatment effect, and the phenomenon of multidrug resistance (MDR) of tumors to drugs appears.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multiple medicine-resistant cell line for lung cancer
  • Multiple medicine-resistant cell line for lung cancer
  • Multiple medicine-resistant cell line for lung cancer

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0005] Specific embodiment one: the multidrug-resistant cell line of lung cancer according to the present embodiment is established according to the following steps: (1) Anip973 cells in the logarithmic growth phase are put into a cell containing 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin In the RPMI-1640 culture medium of prime, put in 37 ℃, CO 2 Cultivate in an environment with a concentration of 5%; (2) 70% to 90% of the inner wall of the culture vessel is covered with Anip973 cells, take Anip973 cells and put them into a culture solution diluted with normal saline and with an NVB concentration of 0.01 to 0.02 μg / mL at 37°C, CO 2 Continue culturing in an environment with a concentration of 5% for 24 hours; (3) Discard the NVB solution, add an equal volume of RPMI-1640 culture solution to continue culturing, and put the surviving Anip973 cells into the logarithmic growth phase after subculture and dilute with normal saline , Increased NVB concen...

specific Embodiment approach 2

[0023] Embodiment 2: The difference between this embodiment and Embodiment 1 is that the concentration of the NVB solution diluted with physiological saline in step (3) is 0.03-0.04 μg / mL. Other steps are the same as those in Embodiment 1.

specific Embodiment approach 3

[0024] Embodiment 3: The difference between this embodiment and Embodiment 1 is: in step (4), repeat operation step (3) 197 to 216 times, each time increasing the concentration of NVB solution by 0.01 μg / mL. Other steps are the same as those in Embodiment 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A multi drug resistance of the lung cancer cell line relates to a multi drug resistance cell line. The invention is to analyze the morphology and biological ethology change of tumour cells after chemotherapy drug resistance, screen the chemotherapy drugs and decide the sensitivity of the chemotherapy drugs, analyze the multi drug resistance mechanism of tumour chemotherapy and screen multidrug resistance reversal agents in vitro, which provides a multi drug resistance of the lung cancer cell line. The establish of the multi drug resistance of the lung cancer cell line includes: (1) placing the Anip973 cells into culture solution containing foetal bovine serum, penicillin and streptomycin and laying them in a environment with a temperature of 37 DEG C and 5% of carbon dioxide concentration; (2) when the Anip973 cells cover 70%-90% of the incubator inwall area, continuing to culture the Anip973 cells in NVB solution with 0.01-0.02 mug / mL for 24h; (3) throwing the NVB solution and adding culture solution with the same volumes, after the generation of the survival Anip973 cells then entering the logarithmic growth phase, continuing to culture for 24h in NVB solution with an increased concentration; (4) repeating the step (3) until the concentration of NVB reach 2.0-2.2 mug / mL, then the Anip973 / NVB cell line is prepared.

Description

technical field [0001] The invention relates to a multidrug-resistant cell line. Background technique [0002] Lung cancer is one of the most common malignant tumors in the world, and its incidence rate ranks first among common malignant tumors, and 80% of the patients are already in the middle and advanced stages when they are diagnosed, and the opportunity for surgical treatment is missed. Navelbine (NVB), namely norvinblastine, is an anti-tumor drug that was only used clinically in the 1990s. It has broad-spectrum anti-tumor activity, especially for the treatment of non-small cell lung cancer (NSCLC). At present, it is one of the most effective drugs for single drug treatment of non-small cell lung cancer, with an effective rate of 30%. The combination of Navelbine and Shunbo for the treatment of lung cancer is currently recognized as one of the most effective chemotherapy regimens. However, there are still some lung cancer patients with poor treatment effect, and the ph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/08C12N5/09
Inventor 陈公琰杨朝阳王萌洪璇
Owner HARBIN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com